What's Going On With Syndax Pharmaceuticals Stock Monday?
Portfolio Pulse from Vandana Singh
Syndax Pharmaceuticals Inc announced topline data from the AUGMENT-101 trial of revumenib in patients with acute myeloid leukemia and acute lymphoid leukemia. The trial met its primary endpoint with a complete remission rate of 23% among the 57 efficacy evaluable patients. However, the company is stopping the trial to further accrual in the KMT2Ar cohorts based on the Independent Data Monitoring Committee recommendation. SNDX shares are down 9.09% at $13.20.
October 02, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Syndax Pharmaceuticals' stock price fell by 9.09% following the announcement of the AUGMENT-101 trial results and the decision to stop the trial for further accrual.
The announcement of the AUGMENT-101 trial results, despite meeting its primary endpoint, coupled with the decision to stop the trial for further accrual, has negatively impacted investor sentiment, leading to a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100